Liver Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part voluntarily and have signed a consent form.
• People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer) either through a tissue/cell test or through clinical guidelines.
• People who have already received immunotherapy as part of treatment before surgery (either to shrink the tumour or to make surgery possible).
• People who have fully recovered from surgical removal of the tumour within the 4 weeks before joining the trial.
• People whose liver is functioning at a level rated Child-Pugh A or B with a score of 7 or below (a measure of liver health — confirm with trial site).
• People with a physical fitness/activity score of 0 or 1 on the ECOG scale (meaning fully active or able to carry out light work — confirm with trial site).
• People whose expected survival is at least 12 weeks.
• People with hepatitis B who are willing to take antiviral medication throughout the study and have regular monitoring; people with active hepatitis C who are already receiving antiviral treatment and whose liver function remains within an acceptable range.

Who may not be able to join:

• People with certain other types of liver or bile duct cancers, or people who have had or currently have another active cancer in the last 5 years (with the exception of certain cured skin cancers or early-stage cervical conditions).
• People whose cancer has spread outside the liver in a way that cannot be controlled, such as to the lungs or brain.
• People who are planning to have, or have previously had, an organ transplant or bone marrow transplant from a donor.
• People who currently have, or have a history of, certain lung conditions such as interstitial lung disease, pulmonary fibrosis, or active pneumonia — or people whose chest scan shows signs of active pneumonia or seriously reduced lung function; people with active tuberculosis.
• People with an active autoimmune disease (where the immune system attacks the body), or a history of one that might return — such as autoimmune hepatitis, certain types of inflammation of the lungs, bowel, eyes, or kidneys, and others. Some milder conditions or well-controlled conditions may still be eligible (confirm with trial site).
• People with high blood pressure that cannot be brought under control with medication (consistently at or above 140/90 mmHg), or people who have previously had a hypertensive crisis or related brain condition.
• People with moderate to severe fluid build-up in the abdomen causing symptoms that require draining, a Child-Pugh liver score above 7, or uncontrolled fluid around the lungs or heart.
• People with certain serious or uncontrolled heart conditions, including significant heart failure, unstable chest pain, a heart attack within the past year, serious heart rhythm problems, or an abnormal heart electrical reading above a certain threshold (confirm with trial site).
• People who have had a liver tumour rupture on its own in the past.
• People who have a history of hepatic encephalopathy (a condition where liver problems affect brain function).
• People with a known immune system deficiency, whether from birth or acquired (such as HIV infection).
• People who have experienced a blood clot, stroke, brain bleed, or pulmonary embolism within the 6 months before starting treatment.
• People who have had gastrointestinal bleeding or a significant risk of it within the 6 months before starting the study, including severe varicose veins in the oesophagus or stomach, active stomach ulcers, or persistently positive stool blood tests that point to a bleeding risk.
• People who have had an abdominal fistula, a hole in the gastrointestinal tract, or an abdominal abscess within the 6 months before starting treatment.
• People with serious wounds that have not healed, active ulcers, or untreated broken bones.
• People with a known tendency to bleed or clot abnormally (such as haemophilia), or people currently taking full-dose blood thinning or clot-dissolving medications (low-dose preventive use of aspirin or low-molecular-weight heparin may be acceptable — confirm with trial site).
• People who have had a major blood vessel problem, such as an aortic aneurysm or arterial clot, within 6 months before surgery.
• People who have had a serious infection within 4 weeks before surgery, or who have been taking antibiotic treatment by mouth or intravenously within 2 weeks before starting the study (preventive antibiotics may be acceptable — confirm with trial site).
• People who have taken immunosuppressive medications or systemic steroid therapy above a certain dose within 14 days before surgery.
• People who have received a live vaccine within 28 days before surgery.
• People who, in the judgement of the research team, have other factors that could affect the study results or their safety, such as alcohol or drug misuse, serious illness including mental health conditions requiring treatment, significantly abnormal lab results, or personal circumstances that could affect their safety.

Important: Always verify eligibility with the trial site directly before applying.